Literature DB >> 19656883

Systemic and mucosal T-lymphocyte activation induced by recombinant adenovirus vaccines in rhesus monkeys.

Yue Sun1, Robert T Bailer, Srinivas S Rao, John R Mascola, Gary J Nabel, Richard A Koup, Norman L Letvin.   

Abstract

The administration of vectors designed to elicited cell-mediated immune responses may have other consequences that are clinically significant. To explore this possibility, we evaluated T-cell activation during the first 2 months after recombinant adenovirus serotype 5 (rAd5) prime or boost immunizations in rhesus monkeys. We also evaluated the kinetics of T-lymphocyte activation in both the systemic and the mucosal compartments after rAd5 administration in monkeys with preexisting immunity to Ad5. The rAd5 immunization induced lower-frequency Gag epitope-specific CD8+ T cells in the colonic mucosa than in the peripheral blood. There was evidence of an expansion of the simian immunodeficiency virus Gag-specific CD8+ T-cell responses, but not the Ad5 hexon-specific T-cell responses, following a homologous rAd5 boost. A striking but transient T-lymphocyte activation in both the systemic and the mucosal compartments of rhesus monkeys was observed after rAd5 immunization. These findings indicate that the administration of a vaccine vector such as Ad5 can induce a global activation of T cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19656883      PMCID: PMC2753133          DOI: 10.1128/JVI.01170-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  15 in total

1.  Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors.

Authors:  Mieke C Sprangers; Wandena Lakhai; Wouter Koudstaal; Marielle Verhoeven; Björn F Koel; Ronald Vogels; Jaap Goudsmit; Menzo J E Havenga; Stefan Kostense
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

2.  Virus-specific cellular immune correlates of survival in vaccinated monkeys after simian immunodeficiency virus challenge.

Authors:  Yue Sun; Jörn E Schmitz; Adam P Buzby; Brianne R Barker; Srinivas S Rao; Ling Xu; Zhi-Yong Yang; John R Mascola; Gary J Nabel; Norman L Letvin
Journal:  J Virol       Date:  2006-08-30       Impact factor: 5.103

3.  Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes.

Authors:  J E Schmitz; M J Kuroda; S Santra; V G Sasseville; M A Simon; M A Lifton; P Racz; K Tenner-Racz; M Dalesandro; B J Scallon; J Ghrayeb; M A Forman; D C Montefiori; E P Rieber; N L Letvin; K A Reimann
Journal:  Science       Date:  1999-02-05       Impact factor: 47.728

4.  Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys.

Authors:  Norman L Letvin; John R Mascola; Yue Sun; Darci A Gorgone; Adam P Buzby; Ling Xu; Zhi-Yong Yang; Bimal Chakrabarti; Srinivas S Rao; Jörn E Schmitz; David C Montefiori; Brianne R Barker; Fred L Bookstein; Gary J Nabel
Journal:  Science       Date:  2006-06-09       Impact factor: 47.728

5.  Magnitude and quality of vaccine-elicited T-cell responses in the control of immunodeficiency virus replication in rhesus monkeys.

Authors:  Yue Sun; Sampa Santra; Jörn E Schmitz; Mario Roederer; Norman L Letvin
Journal:  J Virol       Date:  2008-06-25       Impact factor: 5.103

6.  Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys.

Authors:  Norman L Letvin; Yue Huang; Bimal K Chakrabarti; Ling Xu; Michael S Seaman; Kristin Beaudry; Birgit Korioth-Schmitz; Faye Yu; Daniela Rohne; Kristi L Martin; Ayako Miura; Wing-Pui Kong; Zhi-Yong Yang; Rebecca S Gelman; Olga G Golubeva; David C Montefiori; John R Mascola; Gary J Nabel
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

Review 7.  Critical issues in mucosal immunity for HIV-1 vaccine development.

Authors:  Barton F Haynes; Robin J Shattock
Journal:  J Allergy Clin Immunol       Date:  2008-05-12       Impact factor: 10.793

8.  HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells.

Authors:  Michael R Betts; Martha C Nason; Sadie M West; Stephen C De Rosa; Stephen A Migueles; Jonathan Abraham; Michael M Lederman; Jose M Benito; Paul A Goepfert; Mark Connors; Mario Roederer; Richard A Koup
Journal:  Blood       Date:  2006-02-07       Impact factor: 22.113

9.  Analysis of Gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex.

Authors:  M J Kuroda; J E Schmitz; D H Barouch; A Craiu; T M Allen; A Sette; D I Watkins; M A Forman; N L Letvin
Journal:  J Exp Med       Date:  1998-05-04       Impact factor: 14.307

10.  Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans.

Authors:  Kara L O'Brien; Jinyan Liu; Sharon L King; Ying-Hua Sun; Joern E Schmitz; Michelle A Lifton; Natalie A Hutnick; Michael R Betts; Sheri A Dubey; Jaap Goudsmit; John W Shiver; Michael N Robertson; Danilo R Casimiro; Dan H Barouch
Journal:  Nat Med       Date:  2009-07-20       Impact factor: 53.440

View more
  7 in total

1.  Accelerated heterologous adenovirus prime-boost SIV vaccine in neonatal rhesus monkeys.

Authors:  Jinyan Liu; Hualin Li; M Justin Iampietro; Dan H Barouch
Journal:  J Virol       Date:  2012-05-16       Impact factor: 5.103

Review 2.  Novel adenovirus vector-based vaccines for HIV-1.

Authors:  Dan H Barouch
Journal:  Curr Opin HIV AIDS       Date:  2010-09       Impact factor: 4.283

3.  Durable mucosal simian immunodeficiency virus-specific effector memory T lymphocyte responses elicited by recombinant adenovirus vectors in rhesus monkeys.

Authors:  Hualin Li; Jinyan Liu; Angela Carville; Keith G Mansfield; Diana Lynch; Dan H Barouch
Journal:  J Virol       Date:  2011-09-14       Impact factor: 5.103

Review 4.  Determinants of protection among HIV‐exposed seronegative persons: an overview.

Authors:  Michael M Lederman; Galit Alter; Demetre C Daskalakis; Benigno Rodriguez; Scott F Sieg; Gareth Hardy; Michael Cho; Donald Anthony; Clifford Harding; Aaron Weinberg; Robert H Silverman; Daniel C Douek; Leonid Margolis; David B Goldstein; Mary Carrington; James J Goedert
Journal:  J Infect Dis       Date:  2010-11-01       Impact factor: 5.226

5.  Balancing Trained Immunity with Persistent Immune Activation and the Risk of Simian Immunodeficiency Virus Infection in Infant Macaques Vaccinated with Attenuated Mycobacterium tuberculosis or Mycobacterium bovis BCG Vaccine.

Authors:  Kara Jensen; Myra Grace Dela Pena-Ponce; Michael Piatak; Rebecca Shoemaker; Kelli Oswald; William R Jacobs; Glenn Fennelly; Carissa Lucero; Katie R Mollan; Michael G Hudgens; Angela Amedee; Pamela A Kozlowski; Jacob D Estes; Jeffrey D Lifson; Koen K A Van Rompay; Michelle Larsen; Kristina De Paris
Journal:  Clin Vaccine Immunol       Date:  2017-01-05

6.  A serological survey of human adenovirus serotype 2 and 5 circulating pediatric populations in Changchun, China, 2011.

Authors:  Bin Yu; Zhen Wang; Jianing Dong; Chu Wang; Lina Gu; Caijun Sun; Wei Kong; Xianghui Yu
Journal:  Virol J       Date:  2012-11-23       Impact factor: 4.099

7.  Infection with host-range mutant adenovirus 5 suppresses innate immunity and induces systemic CD4+ T cell activation in rhesus macaques.

Authors:  Huma Qureshi; Meritxell Genescà; Linda Fritts; Michael B McChesney; Marjorie Robert-Guroff; Christopher J Miller
Journal:  PLoS One       Date:  2014-09-09       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.